ClinicalTrials.gg
CompletedNCT03429400Updated Sep 26, 2019

Study of Oral Morphine Sulfate Administration in Pediatric Subjects

A Phase 3 interventional study of Morphine Sulfate in Pain, Postoperative, sponsored by West-Ward Pharmaceutical. Completed at 1 site in United States. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2019-09-26.

Sponsored by West-Ward Pharmaceutical (part of Hikma Pharmaceuticals) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2019, 7 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 96 studies testing morphine in Pain, Postoperative — 17 open to participants now, 20 under way, 1 of them phase 3. Morphine · Pain, Postoperative.

Enrollment
74th of 96
51 · median 90
Started
2018
with 3 others
Phase 3
3 of 96
none open now
Registered
52nd of 96
by date

Among the 96 studies testing morphine in Pain, Postoperative, this one is the 74th largest by enrollment, is one of 4 that started in 2018, is one of 3 in phase 3, and was the 52nd registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

17 of the 96 studies testing morphine in Pain, Postoperative are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About morphine

Morphine: first FDA approval 1984 (DURAMORPH PF). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies testing morphine in Pain, Postoperative, or all of them as a file.
02

Study summary

This is a multicenter, open-label study to evaluate the safety and PK of oral morphine sulfate in pediatric subjects with post-operative pain.

03

Conditions studied

  • Pain, Postoperative

Browse trials for

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has a parent or guardian providing written parental permission/, with subject assent (if required by local IRB).
  2. Has an age-appropriate pain score of ≥4 prior to receiving first dose of study drug.
  3. Is a child 2 years old through 17 years old, inclusive (at the time of informed consent signing).
  4. Weighs at least 10 kg.
  5. Has a routine pediatric procedure that is expected to require inpatient hospitalization postoperatively.
  6. Must be an inpatient for the study treatment period.
  7. Is expected by the investigator to have moderate to severe postoperative pain requiring the use of oral opioids for treatment.
  8. Has the ability to read and understand the study procedures and has the ability to communicate meaningfully with the study investigator and staff (if the subject is of preverbal age or cannot read or communicate meaningfully, then the subject's parent or guardian must meet this criterion).
  9. Is able to tolerate oral medications within 48 hours of surgery.
  10. If female subject is of , she must have a negative urine pregnancy test result on the day of surgery prior to surgery. In this population, female of childbearing potential is defined by the onset of menarche, ie, menstruation, whether at irregular or regular intervals (periods).
  11. Female subjects of childbearing potential and male subjects with partners capable of reproduction must agree to use an effective method as follows from the time of Screening through 30 days after the last dose of study drug:

    • A highly effective method of contraception, including hormonal contraceptives (eg, combined oral contraceptives, patch, vaginal ring, injectables, and implants), intrauterine device or intrauterine system OR
    • An effective double-barrier contraceptive method (2 of the following: male condom, female condom, cervical cap, diaphragm, or contraceptive sponge) OR
    • Abstinence
  12. Must have vascular access to facilitate blood draws.

Exclusion criteria

Exclusion Criteria:

  1. Has significant medical disease(s), laboratory abnormalities, or conditions(s) that in the investigator's judgment could compromise the subject's welfare, ability to communicate with study staff, complete study activities, or would otherwise contraindicate study participation. There is no minimum value for SpO2 for inclusion in the study; this should be based on the investigator's judgment.
  2. Has used opioids chronically (eg, codeine, morphine, oxycodone, or hydromorphone), for >7 calendar days within the previous 30 days prior to surgery.
  3. Has received codeine, hydrocodone, morphine or oxycodone in any form in the previous 7 calendar days prior to surgery.
  4. Is undergoing procedure for treatment of acute burns.
  5. Has known or to receiving oral opioid(s).
  6. Has a current active enteral malabsorption disorder.
  7. Has impaired liver function (eg, [ALT] ≥3 times the [ULN], or total ≥2 times ULN [except patients with evidence of Gilbert's syndrome]), known active hepatic disease (eg, hepatitis), evidence of chronic liver disease or other condition affecting the liver (eg, chronic hepatitis) that may suggest the potential for an increased susceptibility to hepatic toxicity with oral morphine exposure. Subjects with no previous history of liver function impairment may be enrolled prior to receipt of screening laboratory testing results.
  8. Has significantly impaired renal function or disease, as evidenced by an estimated (ie, from creatinine levels using the Schwartz formula) calculated to be less than one-third of normal for the applicable age of this study population. Subjects with no previous history of kidney function impairment may be enrolled prior to receipt of screening laboratory testing results.
  9. Has a history of substance abuse or there is evidence of current substance abuse, in the investigator's opinion.
  10. Has received epidural or regional anesthesia within 12 hours prior to the first dose of study drug.
  11. Has participated in an interventional clinical study ( or marketed product) within 30 days before screening, or plans to participate in another clinical trial in the next 30 days.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Other
    Morphine Sulfate

    oral morphine sulfate tablets oral morphine sulfate oral solution

    Drug: Morphine Sulfate

Interventions

  • Morphine every 4 hours as needed for up to a maximum of 5 days

06

What researchers measure

Primary outcomes

  1. Measurement of Maximum Plasma Concentration [Cmax]

    Eight PK samples will be collected within the first 24 hours after the first dose

    Time frame: 24 hours

  2. Measurement of Area Under the Curve [AUC]

    Eight PK samples will be collected within the first 24 hours after the first dose

    Time frame: 24 hours

  3. Number of Subjects who experience any AEs that lead to study discontinuation

    Time frame: 6 days

  4. Number of subjects who experience serious adverse events

    Time frame: 6 days

  5. Number of subjects with a UMSS sedation score of 4

    Time frame: 6 days

Secondary outcomes

  1. Number of subjects who experience any AEs of special interest

    AEs of special interest include but not limited to sedation, respiratory depression, nausea, vomiting, and pruritus of moderate-to-severe intensity/grade

    Time frame: 6 days

  2. Percentage of subjects with clinically significant decreases in SpO2

    Time frame: 6 days

  3. Number of subject who experience significant change in respiratory rate

    Time frame: 6 days

07

Study locations

1 site
  • Site 105
    Sheffield, Alabama 35660, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in May 2019, 13 months.

Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 13 months is close to that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2018
First posted
Feb 12, 2018
StartActual
Apr 17, 2018
Primary completionActual
May 29, 2019
CompletionActual
May 29, 2019
Last update
Sep 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03429400
Collaborators
Premier Research Group plc
Responsible party
Sponsor
First posted
Feb 12, 2018
Start date
Apr 17, 2018
Primary completion
May 29, 2019
Completion
May 29, 2019
Last update
Sep 26, 2019

Study contacts

Susanne Schmidt, MD,PhD
study director · Premier Research Group plc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Morphine

Start the discussion